Author: Jay Clemens|| Date Published: October 3, 2016
The Department of Health and Human Services has awarded Emergent BioSolutions a five-year, $198.7 million contract to further mature the development of an anthrax vaccine in preparation for a Food and Drug Administration license.
The HHS office of the assistant secretary for preparedness and response™s Biomedical Advanced Research and Development Authority and Emergent BioSolutions will work to validate the effect of the vaccine candidate NuThrax and verify its safety as part of the contract, HHS said Friday.
“BARDA is sponsoring the development of NuThrax to help better protect our nation from [anthrax], ” said Richard Hatchett, acting director of BARDA.
“This vaccine could provide protection in fewer doses than the anthrax vaccine currently available, potentially producing better health outcomes if it was needed during a public health emergency.”
HHS said two doses of NuThrax administered at an interval of 14 days could trigger a protective immune response against anthrax.
The contract also covers the vaccine™s purchase in the future for the Strategic National Stockpile, which also includes the original formulation called BioThrax.
NuThrax includes the adjuvant CPG 7909 in effort to lessen the number of antigens and doses needed to stimulate the immune system.
Brian Meyer, federal field chief technology officer at Axonius Federal, said cybersecurity asset management could help government agencies make dozens…
“Technology transformation company Red River has acquired Invictus International Consulting to expand its cybersecurity and enterprise modernization capabilities to support…
Synergy ECP, a software engineering, cybersecurity and systems engineering services provider, has acquired NetServices, a company offering secure, mission-focused technology services. The…
Precision Aerospace & Defense Group and FACT II Acquisition, a special purpose acquisition company, have signed a definitive business combination agreement to…
LMI has announced the acquisition of intellectual property and advanced capabilities to broaden its in-transit visibility and asset tracking services for…
The Department of Health and Human Services has awarded Emergent BioSolutions a five-year, $198.7 million contract to further mature the development of an anthrax vaccine in preparation for a Food and Drug Administration license.
